Cyxone AB Logo

Cyxone AB

A clinical-stage biotech developing therapies for autoimmune and autoinflammatory diseases.

CYXO | ST

Overview

Corporate Details

ISIN(s):
SE0007815428 (+2 more)
LEI:
54930034OH16ROAY4K87
Country:
Sweden
Address:
Hyllie Boulevard 34, 215 32 Malmö

Description

Cyxone AB is a clinical-stage biotechnology company focused on developing disease-modifying therapies for autoimmune and autoinflammatory diseases. The company's portfolio includes two primary drug candidates in clinical development. Rabeximod is an immunomodulating agent being investigated for the treatment of rheumatoid arthritis. T20K is a drug candidate for multiple sclerosis, developed using the company's cyclotide technology platform, which is based on stable, plant-derived peptides. Cyxone aims to develop therapies that can significantly improve the quality of life for patients with these chronic conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cyxone AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cyxone AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cyxone AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-06-28 Carl Magnus Högerkorp Other Buy 64,950 40,788.60 SEK
2023-06-27 Carl Magnus Högerkorp Other Buy 6,050 3,690.50 SEK
2023-03-03 Carl Magnus Högerkorp Other Buy 100,010 51,005.10 SEK
2023-03-02 Carl Magnus Högerkorp Other Buy 10,873 5,653.96 SEK
2021-07-15 Bert Junno Other Other 1,788,732 7,763,096.88 SEK
2021-07-15 Bert Junno Other Other 1,788,732 N/A
2021-07-14 Bert Junno Other Other 1,788,786 7,790,163.03 SEK
2021-07-14 Bert Junno Other Other 1,788,786 N/A
2021-07-12 Mikeoo Holding AB Other Other 1,788,732 7,441,125.12 SEK
2021-07-12 Mikael Lindstam Other Other 1,788,732 N/A

Peer Companies

Elicio Therapeutics, Inc. Logo
Clinical-stage biotech developing lymph node-targeted immunotherapies for cancer.
United States of America
ELTX
E-Novia Logo
A venture studio and consultancy that transforms Physical AI research into products.
Italy
E9IA
Ensysce Biosciences, Inc. Logo
Clinical-stage pharma firm developing abuse-deterrent drugs for severe pain.
United States of America
ENSC
Enveric Biosciences, Inc. Logo
Develops novel small-molecule therapeutics for neuropsychiatric disorders.
United States of America
ENVB
Eone Diagnomics Genome Center Co., Ltd. Logo
A healthcare company specializing in genetic analysis for personalized medicine.
South Korea
245620
Develops hair loss therapies and provides preclinical CRO services.
South Korea
446440
Equillium, Inc. Logo
Clinical-stage biotech developing therapies for autoimmune & inflammatory disorders.
United States of America
EQ
Eurofins-Cerep Logo
Contract research organization for pre-clinical in vitro drug discovery services.
France
ALECR
Evaxion A/S Logo
A clinical-stage TechBio company developing immunotherapies using an AI platform.
United States of America
EVAX
Evogene Ltd. Logo
A computational biology company using AI to develop life-science products.
Israel
EVGN

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.